AZN•benzinga•
AstraZeneca's Tagrisso (Osimertinib) Has Been Recommended For Approval In The European Union For Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer With Unresectable Epidermal Growth Factor Receptor-Mutated Lung Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga